Payment overview · 2025
General Payments
$457.11
7 reported records · 4 companies
Healthcare provider profile · identity verified
Cassandra B Jenkins
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · BRANDON, FL · NPI 1093366445
Verified facts
What the public records show
CMS Open Payments records show Cassandra B Jenkins received $457.11 in general payments during 2025 across 7 reported records.
Axsome Therapeutics, Inc. accounted for 54.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UPTRAVI as an associated drug or biological on 231 records involving 110 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Uptravi by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Xarelto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $249.71 | 54.6% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $130.96 | 28.6% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $54.83 | 12.0% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $21.61 | 4.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $457.11 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $249.71 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $130.96 | 1 | 2025 |
Source payment records
|
|||||
| Image Management Subscription Normalized: image management subscription |
Device | Philips North America LLC | $34.81 | 2 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $21.61 | 1 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $20.02 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | UPTRAVI open payments reported associated product |
CMS Open Payments — General Payments 231 supporting records · 110 recipient NPIs · example record 1174327095 |
Uptravi · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 247 | 93 |
| Levothyroxine Sodium | Levothyroxine Sodium | 238 | 74 |
| Amlodipine Besylate | Amlodipine Besylate | 234 | 93 |
| Atorvastatin Calcium | Atorvastatin Calcium | 218 | 93 |
| Metformin Hcl | Metformin Hcl | 213 | 74 |
| Omeprazole | Omeprazole | 213 | 71 |
| Gabapentin | Gabapentin | 189 | 67 |
| Losartan Potassium | Losartan Potassium | 184 | 75 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 177 | 60 |
| Lisinopril | Lisinopril | 136 | 49 |
| Metoprolol Tartrate | Metoprolol Tartrate | 125 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 121 | 45 |
| Prednisone | Prednisone | 103 | 69 |
| Ozempic | Semaglutide | 102 | 26 |
| Meloxicam | Meloxicam | 83 | 25 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 81 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 79 | 27 |
| Furosemide | Furosemide | 78 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 77 | 26 |
| Alprazolam | Alprazolam | 75 | 25 |
| Simvastatin | Simvastatin | 69 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 66 | 21 |
| Temazepam | Temazepam | 66 | 13 |
| Trazodone Hcl | Trazodone Hcl | 66 | 26 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 65 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 33 |
| Potassium Chloride | Potassium Chloride | 61 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 60 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 58 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 56 | 20 |
| Montelukast Sodium | Montelukast Sodium | 51 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 51 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 49 | 18 |
| Allopurinol | Allopurinol | 48 | 17 |
| Eliquis | Apixaban | 48 | 14 |
| Sildenafil Citrate | Sildenafil Citrate | 47 | 11 |
| Buspirone Hcl | Buspirone Hcl | 46 | 18 |
| Azithromycin | Azithromycin | 45 | 42 |
| Glipizide Er | Glipizide | 42 | 16 |
| Sertraline Hcl | Sertraline Hcl | 41 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 35 |
| Alendronate Sodium | Alendronate Sodium | 38 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | 11 |
| Glipizide | Glipizide | 37 | 12 |
| Atenolol | Atenolol | 35 | 14 |
| Glimepiride | Glimepiride | 35 | suppressed |
| Carvedilol | Carvedilol | 34 | 15 |
| Donepezil Hcl | Donepezil Hcl | 33 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 33 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | suppressed |
| Finasteride | Finasteride | 30 | suppressed |
| Nitroglycerin | Nitroglycerin | 30 | suppressed |
| Nifedipine Er | Nifedipine | 29 | 11 |
| Jardiance | Empagliflozin | 28 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 28 | 15 |
| Metformin Hcl Er | Metformin Hcl | 26 | 12 |
| Baclofen | Baclofen | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 20 |
| Ezetimibe | Ezetimibe | 24 | 12 |
| Meclizine Hcl | Meclizine Hcl | 24 | 12 |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | 11 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Famotidine | Famotidine | 22 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 20 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 17 |
| Risperidone | Risperidone | 18 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Benzonatate | Benzonatate | 15 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Edarbi | Azilsartan Medoxomil | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | 11 |
| Latanoprost | Latanoprost | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 11 |
| Lovastatin | Lovastatin | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 11 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Uptravi | Selexipag | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $457.11 · 7 records | Axsome Therapeutics, Inc. | Auvelity, BOTOX, Image Management Subscription, SPRAVATO, Vest Therapy Und | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Janssen Pharmaceuticals, Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error